UC Davis Develops LSD Analog JRT With Breakthrough Neuroplastic Benefits and Reduced Hallucinogenic Risks
Recent studies confirm JRT's potent antidepressant effects, cognitive benefits, and safety profile, marking a significant step forward in neuropsychiatric treatment research.
- JRT, a novel LSD analog created by UC Davis researchers, enhances neuroplasticity while avoiding hallucinogenic effects, making it a promising therapeutic candidate for schizophrenia and other brain disorders.
- Preclinical studies in mice revealed a 46% increase in dendritic spine density and an 18% rise in synapse density in the prefrontal cortex, key markers of improved neural connectivity.
- JRT demonstrated robust antidepressant effects, reported to be 100 times more potent than ketamine, and improved cognitive flexibility in behavioral tests relevant to schizophrenia treatment.
- The drug's design involved flipping the position of two atoms in LSD's molecular structure, significantly reducing hallucinogenic potential while retaining therapeutic efficacy.
- Ongoing research aims to optimize JRT's synthesis, explore its application for other neuropsychiatric and neurodegenerative conditions, and develop additional analogs for broader therapeutic use.
Medical Xpress 
GEN 
Neuroscience News 
Interesting Engineering 